Nipocalimab news

All news on Nipocalimab (also known as M281): plants, production capacities, investments and involved companies.

3 June 2026

Johnson & Johnson: nipocalimab lowers SLE disease activity in Phase 2 JASMINE study

Phase 2 data show FcRn blocker nipocalimab reduced SLE activity versus placebo, with larger benefit in autoantibody‑positive patients and no new safety signals.
27 April 2026

Johnson & Johnson’s IMAAVY granted FDA Priority Review for wAIHA

FDA granted Priority Review to nipocalimab sBLA for warm autoimmune hemolytic anemia after Phase 2/3 ENERGY showed durable hemoglobin responses and fatigue improvement; review ~6 months.

Who will be producing Nipocalimab in the future?

Find out with chemXplore Alpha

Learn more